Peripheral Neuropathic Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Trevena, Afasci, Lexicon Pharma, Haisco Pharma, Vertex Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Peripheral Neuropathic Pain pipeline constitutes 10+ key companies continuously working towards developing 12+ Peripheral Neuropathic Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Peripheral Neuropathic Pain Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral Neuropathic Pain Market.

The Peripheral Neuropathic Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Peripheral Neuropathic Pain Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Peripheral Neuropathic Pain treatment therapies with a considerable amount of success over the years.

*
Peripheral Neuropathic Pain companies working in the treatment market are Trevena, Afasci, Lexicon Pharmaceuticals, Haisco Pharmaceutical, Vertex Pharmaceuticals, AlzeCure Pharma, Yuhan Corporation, Shanghai SIMR Biotech, GlaxoSmithKline, Lexicon Pharma, Jemincare, Eli Lilly and Company, Haisco Pharmaceutical, Aptinyx, Daiichi Sankyo, and others, are developing therapies for the Peripheral Neuropathic Pain treatment

*
Emerging Peripheral Neuropathic Pain therapies in the different phases of clinical trials are- TRV045, AFA-281, LX9211, HSK16149, VX-548, ACD440 Gel, YHD1119, SR419, GW856553, LX9211 (blinded), JMKX000623, LY3857210, HSK16149, NYX-2925, DS-5565, Suzetrigine, and others are expected to have a significant impact on the Peripheral Neuropathic Pain market in the coming years.

*
In November 2024, Sangamo Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ST-503, an experimental epigenetic therapy aimed at treating intractable pain caused by idiopathic small fiber neuropathy (iSFN)-a form of chronic neuropathic pain.

Peripheral Neuropathic Pain Overview

Peripheral Neuropathic Pain is a type of chronic pain caused by damage or dysfunction in the peripheral nerves, which are the nerves outside the brain and spinal cord. It often results from conditions like diabetes (diabetic neuropathy), shingles (postherpetic neuralgia), trauma, or infections. Symptoms include burning, tingling, numbness, shooting pain, or heightened sensitivity in the affected areas. This pain can significantly impact quality of life. Treatment typically involves pain-relief medications, nerve-targeting drugs like anticonvulsants or antidepressants, and sometimes nerve blocks or physical therapy.

Get a Free Sample PDF Report to know more about Peripheral Neuropathic Pain Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/peripheral-neuropathic-pain-pipeline-insight [https://www.delveinsight.com/report-store/peripheral-neuropathic-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Peripheral Neuropathic Pain Drugs Under Different Phases of Clinical Development Include:

*
TRV045: Trevena

*
AFA-281: Afasci

*
LX9211: Lexicon Pharmaceuticals

*
HSK16149: Haisco Pharmaceutical

*
VX-548: Vertex Pharmaceuticals

*
ACD440 Gel: AlzeCure Pharma

*
YHD1119: Yuhan Corporation

*
SR419: Shanghai SIMR Biotech

*
GW856553: GlaxoSmithKline

*
LX9211 (blinded): Lexicon Pharma

*
JMKX000623: Jemincare

*
LY3857210: Eli Lilly and Company

*
HSK16149: Haisco Pharmaceutical

*
NYX-2925: Aptinyx

*
DS-5565: Daiichi Sankyo

*
Suzetrigine: Vertex Pharmaceuticals

Peripheral Neuropathic Pain Route of Administration

Peripheral Neuropathic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Peripheral Neuropathic Pain Molecule Type

Peripheral Neuropathic Pain Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Peripheral Neuropathic Pain Pipeline Therapeutics Assessment

*
Peripheral Neuropathic Pain Assessment by Product Type

*
Peripheral Neuropathic Pain By Stage and Product Type

*
Peripheral Neuropathic Pain Assessment by Route of Administration

*
Peripheral Neuropathic Pain By Stage and Route of Administration

*
Peripheral Neuropathic Pain Assessment by Molecule Type

*
Peripheral Neuropathic Pain by Stage and Molecule Type

DelveInsight's Peripheral Neuropathic Pain Report covers around 12+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Peripheral Neuropathic Pain product details are provided in the report. Download the Peripheral Neuropathic Pain pipeline report to learn more about the emerging Peripheral Neuropathic Pain therapies [https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Peripheral Neuropathic Pain Therapeutics Market include:

Key companies developing therapies for Peripheral Neuropathic Pain are - Eli Lilly, Teva Pharma, Pfizer, Novartis, Johnson & Johnson, GlaxoSmithKline, Medtronic, and others.

Peripheral Neuropathic Pain Pipeline Analysis:

The Peripheral Neuropathic Pain pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral Neuropathic Pain with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral Neuropathic Pain Treatment.

*
Peripheral Neuropathic Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Peripheral Neuropathic Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral Neuropathic Pain market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Peripheral Neuropathic Pain drugs and therapies [https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Peripheral Neuropathic Pain Pipeline Market Drivers

*
High Prevalence and Growing Patient Pool, Advancements in Drug Development, are some of the important factors that are fueling the Peripheral Neuropathic Pain Market.

Peripheral Neuropathic Pain Pipeline Market Barriers

*
However, Limited Efficacy of Existing Treatments, High Treatment Costs and Access Challenges, and other factors are creating obstacles in the Peripheral Neuropathic Pain Market growth.

Scope of Peripheral Neuropathic Pain Pipeline Drug Insight

*
Coverage: Global

*
Key Peripheral Neuropathic Pain Companies: Trevena, Afasci, Lexicon Pharmaceuticals, Haisco Pharmaceutical, Vertex Pharmaceuticals, AlzeCure Pharma, Yuhan Corporation, Shanghai SIMR Biotech, GlaxoSmithKline, Lexicon Pharma, Jemincare, Eli Lilly and Company, Haisco Pharmaceutical, Aptinyx, Daiichi Sankyo, and others

*
Key Peripheral Neuropathic Pain Therapies: TRV045, AFA-281, LX9211, HSK16149, VX-548, ACD440 Gel, YHD1119, SR419, GW856553, LX9211 (blinded), JMKX000623, LY3857210, HSK16149, NYX-2925, DS-5565, Suzetrigine, and others

*
Peripheral Neuropathic Pain Therapeutic Assessment: Peripheral Neuropathic Pain current marketed and Peripheral Neuropathic Pain emerging therapies

*
Peripheral Neuropathic Pain Market Dynamics: Peripheral Neuropathic Pain market drivers and Peripheral Neuropathic Pain market barriers

Request for Sample PDF Report for Peripheral Neuropathic Pain Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Peripheral Neuropathic Pain Report Introduction

2. Peripheral Neuropathic Pain Executive Summary

3. Peripheral Neuropathic Pain Overview

4. Peripheral Neuropathic Pain- Analytical Perspective In-depth Commercial Assessment

5. Peripheral Neuropathic Pain Pipeline Therapeutics

6. Peripheral Neuropathic Pain Late Stage Products (Phase II/III)

7. Peripheral Neuropathic Pain Mid Stage Products (Phase II)

8. Peripheral Neuropathic Pain Early Stage Products (Phase I)

9. Peripheral Neuropathic Pain Preclinical Stage Products

10. Peripheral Neuropathic Pain Therapeutics Assessment

11. Peripheral Neuropathic Pain Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Peripheral Neuropathic Pain Key Companies

14. Peripheral Neuropathic Pain Key Products

15. Peripheral Neuropathic Pain Unmet Needs

16 . Peripheral Neuropathic Pain Market Drivers and Barriers

17. Peripheral Neuropathic Pain Future Perspectives and Conclusion

18. Peripheral Neuropathic Pain Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=peripheral-neuropathic-pain-pipeline-2025-fda-updates-therapy-innovations-and-clinical-trial-landscape-analysis-by-delveinsight-trevena-afasci-lexicon-pharma-haisco-pharma-vertex-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.